Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (also referenced as Chemomab Therapeutics Ltd. in metadata) covers the month of November 2019, with specific disclosures dated November 15, 2019. The Company is a foreign private issuer focused on gene therapy, specifically evaluating inodiftagene vixteplasmid for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC).
Key Financial Metrics
The filing announces the release of third-quarter 2019 financial results via a press release (Exhibit 99.2) but does not contain specific numerical data within the text of this report. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Discontinuation of Clinical Trial: The Company discontinued its Phase 2 Codex study evaluating inodiftagene vixteplasmid. Analysis indicated a low probability of surpassing the pre-defined futility threshold (10 complete responses in 35 patients) at the interim analysis.
- Efficacy Concerns: Data suggests a low probability of achieving an efficacy profile necessary to support regulatory approval.
- Leadership Change: The Board of Directors appointed Dennison Veru as interim Chairman of the Board, effective immediately.
Guidance, Outlook, and Risks
The discontinuation of the Codex study represents a significant negative development for the Company's primary pipeline asset. Management determined that the probability of regulatory approval based on current data is low. The filing does not provide updated financial guidance or specific future operational plans beyond the leadership appointment and the cessation of the specific trial.
Investor Verification Checklist
- Review Exhibit 99.2 for specific Q3 2019 financial figures (cash position, burn rate, and revenue) not included in this summary.
- Verify the Company's remaining cash runway and capital requirements following the discontinuation of the Phase 2 study.
- Assess the impact of the interim Chairman appointment on future strategic direction.
- Confirm if the Company has alternative candidates or a revised development plan for NMIBC.